Free Trial

Passage Bio (PASG) Competitors

Passage Bio logo
$0.39 -0.04 (-9.07%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$0.40 +0.00 (+1.02%)
As of 06/13/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PASG vs. PROC, SGMT, IOBT, CABA, IMAB, SAVA, VXRT, CRDL, KRRO, and VIRI

Should you be buying Passage Bio stock or one of its competitors? The main competitors of Passage Bio include Procaps Group (PROC), Sagimet Biosciences (SGMT), IO Biotech (IOBT), Cabaletta Bio (CABA), I-Mab (IMAB), Cassava Sciences (SAVA), Vaxart (VXRT), Cardiol Therapeutics (CRDL), Korro Bio (KRRO), and Virios Therapeutics (VIRI). These companies are all part of the "pharmaceutical products" industry.

Passage Bio vs. Its Competitors

Procaps Group (NASDAQ:PROC) and Passage Bio (NASDAQ:PASG) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, analyst recommendations, media sentiment, institutional ownership, community ranking and earnings.

Procaps Group has higher revenue and earnings than Passage Bio.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Procaps Group$409.92M0.26$42.54MN/AN/A
Passage BioN/AN/A-$102.06M-$1.02-0.38

Procaps Group's return on equity of 0.00% beat Passage Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Procaps GroupN/A N/A N/A
Passage Bio N/A -72.53%-52.10%

53.5% of Passage Bio shares are held by institutional investors. 19.9% of Procaps Group shares are held by insiders. Comparatively, 5.0% of Passage Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Passage Bio has a consensus target price of $7.50, suggesting a potential upside of 1,818.16%. Given Passage Bio's stronger consensus rating and higher probable upside, analysts plainly believe Passage Bio is more favorable than Procaps Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Procaps Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Passage Bio
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00

Procaps Group has a beta of -0.05, suggesting that its stock price is 105% less volatile than the S&P 500. Comparatively, Passage Bio has a beta of 1.71, suggesting that its stock price is 71% more volatile than the S&P 500.

Passage Bio received 50 more outperform votes than Procaps Group when rated by MarketBeat users. Likewise, 68.83% of users gave Passage Bio an outperform vote while only 37.50% of users gave Procaps Group an outperform vote.

CompanyUnderperformOutperform
Procaps GroupOutperform Votes
3
37.50%
Underperform Votes
5
62.50%
Passage BioOutperform Votes
53
68.83%
Underperform Votes
24
31.17%

In the previous week, Passage Bio had 1 more articles in the media than Procaps Group. MarketBeat recorded 1 mentions for Passage Bio and 0 mentions for Procaps Group. Passage Bio's average media sentiment score of 1.87 beat Procaps Group's score of 0.00 indicating that Passage Bio is being referred to more favorably in the news media.

Company Overall Sentiment
Procaps Group Neutral
Passage Bio Very Positive

Summary

Passage Bio beats Procaps Group on 9 of the 14 factors compared between the two stocks.

Get Passage Bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for PASG and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PASG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PASG vs. The Competition

MetricPassage BioBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$24.30M$3.09B$5.57B$8.50B
Dividend YieldN/A1.56%5.27%4.17%
P/E Ratio-0.3332.6326.7519.66
Price / SalesN/A455.18403.98152.07
Price / CashN/A168.6838.2534.64
Price / Book0.193.366.964.59
Net Income-$102.06M-$72.35M$3.23B$248.23M
7 Day Performance-7.52%0.36%-1.22%-1.07%
1 Month Performance31.47%16.10%6.34%2.59%
1 Year Performance-62.76%-15.37%33.05%13.50%

Passage Bio Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PASG
Passage Bio
2.7563 of 5 stars
$0.39
-9.1%
$7.50
+1,818.2%
-62.8%$24.30MN/A-0.33130Positive News
Gap Down
PROC
Procaps Group
N/A$0.95
-40.3%
N/A-63.5%$107.18M$409.92M0.004,900Gap Down
High Trading Volume
SGMT
Sagimet Biosciences
2.336 of 5 stars
$3.49
-1.7%
$22.40
+541.8%
+99.8%$107.06M$2M-1.988
IOBT
IO Biotech
3.8242 of 5 stars
$1.62
+14.1%
$9.33
+476.1%
+3.1%$106.73MN/A-1.1830News Coverage
Analyst Upgrade
Short Interest ↓
High Trading Volume
CABA
Cabaletta Bio
2.8663 of 5 stars
$2.06
+10.2%
$20.33
+887.1%
-81.3%$104.53MN/A-0.9650News Coverage
Analyst Forecast
Analyst Revision
Gap Down
IMAB
I-Mab
3.0882 of 5 stars
$1.28
-2.3%
$5.50
+329.7%
+35.3%$104.53M$3.27M0.00380News Coverage
Gap Down
SAVA
Cassava Sciences
4.2692 of 5 stars
$2.13
+6.0%
$54.50
+2,458.7%
-89.6%$102.90MN/A-1.5430Positive News
VXRT
Vaxart
2.0829 of 5 stars
$0.45
+3.9%
$3.00
+566.7%
+22.6%$102.70M$47.40M-1.10120Gap Down
CRDL
Cardiol Therapeutics
2.253 of 5 stars
$1.24
-0.8%
$8.67
+598.9%
-39.4%$102.44MN/A-3.1820Gap Down
KRRO
Korro Bio
3.536 of 5 stars
$10.80
-5.4%
$102.43
+848.4%
-67.5%$101.42M$4.82M-1.1470Positive News
Analyst Revision
High Trading Volume
VIRI
Virios Therapeutics
0.4321 of 5 stars
$5.18
-2.1%
$3.00
-42.1%
+1,852.1%$99.76MN/A-19.195News Coverage
Gap Up

Related Companies and Tools


This page (NASDAQ:PASG) was last updated on 6/15/2025 by MarketBeat.com Staff
From Our Partners